PhoenixBio Co.,Ltd.JP:6190

Market cap
¥1.8B
P/E ratio
16.8x
Phoenix Bio provides pharmaceutical testing services using PXB mice with human liver cells to help drug companies predict how medicines work in people.
Period EndEBITDA margin (%) YoY (%)
Mar 31, 2025-7.4-449.24%
Mar 31, 20242.1-91.56%
Mar 31, 202325.1-507.85%
Mar 31, 2022-6.1-71.88%
Mar 31, 2021-21.8+206.82%
Mar 31, 2020-7.1-68.97%
Mar 31, 2019-22.9-15.21%
Mar 31, 2018-27.1-298.91%
Mar 31, 201713.6-22.08%
Mar 31, 201617.5+113.09%
Mar 31, 20158.2